FRANKFURT: Pfizer and BioNTech’s COVID-19 vaccine has been given to 140,000 people in Britain, and the feedback on side effects and tolerability has been reassuring, BioNTech’s chief medical officer said on Thursday.
Britain was the first to approve the shot for emergency use on Dec. 3, followed by Canada and the US Food and Drug Administration.
“In Britain, 140,000 people have been vaccinated by now and the tolerability data are exactly as we have shown in our clinical trial,” Chief Medical Officer Oezlem Tuereci said in a webcast call with German Chancellor Angela Merkel.
She said side effects have been mild to moderate and short-lived and similar to those typically seen in other commonly used vaccines.
The German biotech firm’s Chief Executive Ugur Sahin said in the call that he was confident that normal life could resume by next winter.

UK’s vaccine approval raises world’s hopes for COVID-19 fight UK authorizes Pfizer coronavirus vaccine for emergency use

In National Geographic’s “Expedition: Saving Our Seas,” it’s all hands on deck
The ‘hell chicken’ dinosaur was a real terror — to fruit
The brain’s fear center moonlights as the save button for memories
Europe’s Hera mission is ready to double down on asteroid science
Stone Age children left fingerprints on ancient art projects
This magic mushroom can kill
When the rains fail: Preparing for drought in Central America
‘Here, you can eat until you’re full’: Oleshky evacuees savour first proper meals in years
COP31: National Oil Companies Must Lead Global Shift Away from Fossil Fuels, Says NRGI Expert
COP31: Climate finance falls short as calls grow for polluters to pay